Christiansen Hans, Hermann Robert Michael, Martin Alexios, Florez Rodrigo, Kahler Elke, Nitsche Mirko, Hille Andrea, Steiner Wolfgang, Hess Clemens F, Pradier Olivier
Department of Radiotherapy, University of Göttingen, Göttingen, Germany, and Départmentde Cancérologie, Hôpital Morvan, Centre Hospitalier Universitaire de Brest, France.
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1067-74. doi: 10.1016/j.ijrobp.2006.03.007. Epub 2006 Jun 5.
The aim of this study was to evaluate the efficacy of adjuvant radiotherapy after transoral laser microsurgery for advanced recurrent head-and-neck squamous cell carcinoma (HNSCC).
Between 1988 and 2000, 37 patients with advanced local recurrences (23 local and 14 locoregional recurrences) of HNSCC without distant metastases were treated in curative intent with organ-preserving transoral laser microsurgery and adjuvant radiotherapy (before 1994 split-course radiotherapy with carboplatinum, after 1994 conventional radiotherapy). Initial therapy of the primary (8.1% oral cavity, 35.1% oropharynx, 13.5% hypopharynx, and 43.3% larynx) before relapse was organ-preserving transoral laser microsurgery without any adjuvant therapy.
After a median follow-up of 124 months, the 5-year overall survival rate was 21.3%, the loco-regional control rate 48.3%, respectively. In multivariate analysis, stage of original primary tumor (Stage I/II vs. Stage III/IV), and patient age (<58 years vs. >or=58 years) showed statistically significant impact on prognosis. In laryngeal cancer, larynx preservation rate after treatment for recurrent tumor was 50% during follow-up.
Our data show that organ-preserving transoral laser microsurgery followed by adjuvant radiotherapy is a curative option for patients who have advanced recurrence after transoral laser surgery and is an alternative to radical treatment.
本研究旨在评估经口激光显微手术治疗晚期复发性头颈部鳞状细胞癌(HNSCC)后辅助放疗的疗效。
1988年至2000年间,37例无远处转移的晚期局部复发性HNSCC患者(23例为局部复发,14例为区域复发)接受了旨在保留器官的经口激光显微手术及辅助放疗(1994年前采用卡铂分割放疗,1994年后采用常规放疗)。复发前原发灶(8.1%为口腔,35.1%为口咽,13.5%为下咽,43.3%为喉)的初始治疗为保留器官的经口激光显微手术,未进行任何辅助治疗。
中位随访124个月后,5年总生存率为21.3%,局部区域控制率分别为48.3%。多因素分析显示,原发肿瘤分期(I/II期与III/IV期)及患者年龄(<58岁与≥58岁)对预后有统计学显著影响。在喉癌中,复发性肿瘤治疗后的喉保留率在随访期间为50%。
我们的数据表明,经口激光显微手术联合辅助放疗是经口激光手术后出现晚期复发患者的一种治愈性选择,也是根治性治疗的一种替代方案。